LAVVAN

📍 New York, United States👥 7 employees💰 Last funded Jul 2019
Biotechnology Research🌐 lavvan.com
Website LinkedIn
Reimagining the cannabinoid production process to deliver high-quality, reliably sourced and cost-competitive cannabinoid ingredients LAVVAN produces a range of natural cannabinoid ingredients using its advanced cellular agriculture platform which supplies cannabinoids with unparalleled purity, consistency, potency and sustainability to serve a range of industries including health, beauty, food and beverage and pharmaceuticals. Nearly from inception, LAVVAN is led by one of the most influential, respected and pioneering teams in the global cannabis industry. After the $2.5 billion purchase of MedReleaf Corp. – a company that from 2014 to 2018 was one of the largest legal producers of cannabinoids in the world – the team dedicated itself to once again revolutionizing the industry that it helped to birth, by bringing to it a level of quality, reliability and sustainability that global brands, manufacturers and suppliers can depend on.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in LAVVAN?
LAVVAN has 1 investors on record on gritt.io.
When did LAVVAN last raise funding?
The most recent investment in LAVVAN recorded on gritt.io was in July 2019.
What industry is LAVVAN in?
LAVVAN operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is LAVVAN based?
LAVVAN is headquartered in New York, United States.